Trials / Completed
CompletedNCT01910545
Phase 1 Study of OTS167 in Patients With Solid Tumors
PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- OncoTherapy Science, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTS167IV |
Timeline
- Start date
- 2013-08-23
- Primary completion
- 2016-04-11
- Completion
- 2016-05-04
- First posted
- 2013-07-29
- Last updated
- 2017-06-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01910545. Inclusion in this directory is not an endorsement.